Loading organizations...
KAHR Medical, based in Jerusalem, Israel, develops novel Dual Signaling Proteins (DSP), bi-functional fusion proteins to treat cancer and autoimmune diseases by modulating dual biological signals. Its platform includes DSP-Hexamers and DSP-Clusters, with lead candidate DSP107, a second-generation CD47x41BB therapy, in Phase I/II trials for advanced solid tumors, alone and with Roche's Tecentriq. The privately held biotech has raised $18 million in 2020, led by Flerie Invest AB, and $12 million in 2015 for its Series B round. Key investors include Flerie Invest AB, Oriella Ltd., Pavilion Capital, and Mirae Asset Venture Investment, with Yaron Pereg as CEO and Bryan Jennings as CFO. KAHR Medical was founded in 2005. Its business model centers on private biotech funded through equity financings, including Series B rounds.
KAHR medical has raised $62.0M across 3 funding rounds.
KAHR medical has raised $62.0M in total across 3 funding rounds.
KAHR medical has raised $62.0M in total across 3 funding rounds.
KAHR medical's investors include Ted Fjällman, Cancer Focus Fund, Oriella, Peregrine Ventures, SPRIM Global Investments, Flerie Invest, Hadasit Bio-Holdings, Mirae Asset Venture Investment, Pavilion Capital, Korea Investment Partners, DSC Investment.
KAHR medical has raised $62.0M across 3 funding rounds. Most recently, it raised $32.0M Debt / Other Equity in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 8, 2026 | $32M Debt Financing | TED Fjällman, Cancer Focus Fund, Oriella, Peregrine Ventures | Sprim Global Investments | Announced |
| Feb 25, 2020 | $18M Venture Round | Flerie Invest, Hadasit BIO Holdings, Mirae Asset Venture Investment, Oriella, Pavilion Capital | — | Announced |
| Dec 15, 2015 | $12M Series B | — | Korea Investment Partners, DSC Investment, Flerie Invest, Mirae Asset Venture Investment | Announced |
